| scholarly article | Q13442814 |
| P2093 | author name string | Lynn L Silver | |
| P2860 | cites work | Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa | Q42375984 |
| Nucleotide sequence of the fosB gene conferring fosfomycin resistance in Staphylococcus epidermidis | Q42636633 | ||
| Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli | Q43195414 | ||
| CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. | Q43293884 | ||
| Fosfadecin and fosfocytocin, new nucleotide antibiotics produced by bacteria | Q44517824 | ||
| In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance | Q44607486 | ||
| Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance | Q44676765 | ||
| The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors | Q46082809 | ||
| First detection of fosfomycin resistance gene fosA3 in CTX-M-producing Escherichia coli isolates from healthy individuals in Japan | Q46161139 | ||
| Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis | Q47904411 | ||
| The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens--interim report. | Q53331404 | ||
| Fosfomycin monophosphate and fosfomycin diphosphate, two inactivated fosfomycin derivatives formed by gene products of fomA and fomB from a fosfomycin producing organism Streptomyces wedmorensis. | Q54589592 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| Fosfomycin-resistant mutant of Escherichia coli | Q54637966 | ||
| Production of fosfomycin (phosphonomycin) by Pseudomonas syringae | Q69620023 | ||
| Phosphonomycin. IV. Susceptibility testing method and survey | Q71363334 | ||
| Detection and characterization of a phospholactoyl-enzyme adduct in the reaction catalyzed by UDP-N-acetylglucosamine enolpyruvoyl transferase, MurZ | Q72160243 | ||
| Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin | Q72160246 | ||
| Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces | Q72475705 | ||
| Evidence that the reaction of the UDP-N-acetylglucosamine 1-carboxyvinyltransferase proceeds through the O-phosphothioketal of pyruvic acid bound to Cys115 of the enzyme | Q72709263 | ||
| Fosfadecin and fosfocytocin, new nucleotide antibiotics produced by bacteria. | Q78420692 | ||
| Fosfomycin Monophosphate and Fosfomycin Diphosphate, Two Inactivated Fosfomycin Derivatives Formed by Gene Products of fomA and fomB from a Fosfomycin Producing Organism Streptomyces wedmorensis. | Q78422728 | ||
| The ECO*SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report | Q95799925 | ||
| Essential Bacillus subtilis genes | Q24681292 | ||
| Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance | Q26853135 | ||
| Resistance to antibiotics targeted to the bacterial cell wall | Q26859841 | ||
| Functional Consequence of Covalent Reaction of Phosphoenolpyruvate with UDP-N-acetylglucosamine 1-Carboxyvinyltransferase (MurA) | Q27677546 | ||
| Structure and Function of the Genomically Encoded Fosfomycin Resistance Enzyme, FosB, from Staphylococcus aureus | Q27681408 | ||
| Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin | Q27734363 | ||
| MurAA, catalysing the first committed step in peptidoglycan biosynthesis, is a target of Clp-dependent proteolysis in Bacillus subtilis | Q28488903 | ||
| The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa | Q28492495 | ||
| Antimicrobial Susceptibility and Molecular Mechanisms of Fosfomycin Resistance in Clinical Escherichia coli Isolates in Mainland China | Q28547100 | ||
| Distribution of an Inducible Hexose-Phosphate Transport System Among Various Bacteria | Q30451434 | ||
| Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies | Q33436519 | ||
| In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin | Q33558996 | ||
| Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections | Q33564290 | ||
| Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria | Q33601835 | ||
| Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. | Q34096605 | ||
| The mechanism of action of fosfomycin (phosphonomycin) | Q34214482 | ||
| Fosfomycin: use beyond urinary tract and gastrointestinal infections | Q34774778 | ||
| Biological costs and mechanisms of fosfomycin resistance in Escherichia coli | Q35685710 | ||
| Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation | Q35893671 | ||
| Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost | Q35941216 | ||
| Different biosynthetic pathways to fosfomycin in Pseudomonas syringae and Streptomyces species. | Q36171710 | ||
| The discovery of cell wall active antibacterial antibiotics | Q36335002 | ||
| Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of Salmonella typhimurium cya and crp mutants | Q36417093 | ||
| Fosfomycin | Q36675246 | ||
| Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis | Q36702923 | ||
| Plasmid-encoded fosfomycin resistance | Q37187074 | ||
| Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials | Q37768581 | ||
| Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release | Q37866109 | ||
| Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. | Q37957839 | ||
| Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K-12 | Q40145885 | ||
| Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. | Q40697349 | ||
| In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. | Q40698278 | ||
| Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model | Q40810228 | ||
| Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China | Q41633267 | ||
| Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli. | Q42244641 | ||
| P433 | issue | 2 | |
| P577 | publication date | 2017-01-06 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | Fosfomycin: Mechanism and Resistance | |
| P478 | volume | 7 |
| Q88918474 | Cell-Wall Recycling of the Gram-Negative Bacteria and the Nexus to Antibiotic Resistance |
| Q60907366 | Dual-barcoded shotgun expression library sequencing for high-throughput characterization of functional traits in bacteria |
| Q90189782 | Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics |
| Q64116187 | Fosfomycin: the characteristics, activity, and use in critical care |
| Q89982219 | ISEcp1-mediated transposition leading to fosfomycin and broad-spectrum cephalosporins resistance in Klebsiella pneumoniae |
| Q93085303 | Identification of FosA8, a Plasmid-Encoded Fosfomycin Resistance Determinant from Escherichia coli, and Its Origin in Leclercia adecarboxylata |
| Q90281431 | In vitro activity of fosfomycin against Campylobacter isolates from poultry and wild birds |
| Q91361864 | In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia |
| Q41989392 | Inhibition of fosfomycin resistance protein FosA by phosphonoformate (foscarnet) in multidrug-resistant Gram-negative pathogens. |
| Q90477681 | Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada |
| Q97518503 | Molecular Mechanisms and Epidemiology of Fosfomycin Resistance in Staphylococcus aureus Isolated From Patients at a Teaching Hospital in China |
| Q89985089 | Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting |
| Q92613730 | Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase |
| Q88984602 | Proposing Kluyvera georgiana as the Origin of the Plasmid-Mediated Resistance Gene fosA4 |
| Q90567824 | Pyruvate Substitutions on Glycoconjugates |
| Q57470806 | Reaching toward underexplored targets in antibacterial drug design |
| Q52670587 | Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia. |
| Q89068756 | Tet38 Efflux Pump Contributes to Fosfomycin Resistance in Staphylococcus aureus |
| Q92152636 | The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates |
| Q100491035 | Ursolic acid reduces hepatocellular apoptosis and alleviates alcohol-induced liver injury via irreversible inhibition of CASP3 in vivo |
| Q40075723 | Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene |
Search more.